BEAM
Beam Therapeutics Inc

6,261
Mkt Cap
$2.78B
Volume
1.4M
52W High
$35.25
52W Low
$13.53
PE Ratio
-6.20
BEAM Fundamentals
Price
$27.51
Prev Close
$27.40
Open
$27.25
50D MA
$25.09
Beta
1.91
Avg. Volume
2.26M
EPS (Annual)
-$4.58
P/B
2.89
Rev/Employee
$131,507.25
Loading...
Loading...
News
all
press releases
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned an average rating of "Moderate Buy" from the sixteen research firms that are presently covering the company, MarketBeat reports. One...
MarketBeat·2d ago
News Placeholder
Cathie Wood sells $15.8 million of megacap tech stock
Cathie Wood, chief of Ark Investment Management, is making moves in megacap tech stocks. Last month, Wood added to her positions in Nvidia and Google, and this week she trimmed two other names from...
TheStreet.com·4d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 6.8% - What's Next?
Beam Therapeutics (NASDAQ:BEAM) Trading Up 6.8% - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·7d ago
News Placeholder
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
Zacks·13d ago
News Placeholder
14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP
Entropy Technologies LP purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·14d ago
News Placeholder
Beam Therapeutics (BEAM) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·14d ago
News Placeholder
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
Zacks·15d ago
News Placeholder
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Zacks·20d ago

Latest BEAM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.